Let's focus on what we can do!

By Disabled People for Disabled People

  • Home
  • >
  • Bipolar Disorder
  • >
  • RPS warns of ‘huge extra cost’ to NHS after bipolar drug withdrawn – The Pharmaceutical Journal

RPS warns of ‘huge extra cost’ to NHS after bipolar drug withdrawn – The Pharmaceutical Journal

Wednesday, 9 September, 2020

RPS warns of ‘huge extra cost’ to NHS after bipolar drug withdrawn – The Pharmaceutical Journal

Essential Pharma is planning to discontinue production of first-line bipolar disorder treatment Priadel next year, leaving a range of more expensive alternatives on the market.

Source: DR P. MARAZZI/SCIENCE PHOTO LIBRARY
Essential Pharma, the manufacturer of Priadel, has said the drug is no longer a viable product “due to restrictions on permitted pricing”

 
The Royal Pharmaceutical Society (RPS) has said it is ”deeply concerned” and warned of the “huge extra cost” to the NHS after a manufacturer announced plans to discontinue production of one of its branded lithium carbonate products.

In August 2020, Essential Pharma said it would be discontinuing production of Priadel 200mg and 400mg — used as a first-line treatment for bipolar disorder — in April 2021 “due to restrictions on permitted pricing”, making the product “no longer viable”.

Click here to read full article https://www.pharmaceutical-journal.com/news-and-analysis/news/rps-warns-of-huge-extra-cost-to-nhs-after-bipolar-drug-withdrawn/20208308.article

Categories :
  • Bipolar Disorder
  • Latest Headlines
Socials :

Recent posts